ReviewRenal failure2025
Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of protein-supportive therapy on maternal and neonatal outcomes in patients with nephrotic syndrome during pregnancy.American journal of translational research · 2026Article
- Healthy birth after chemotherapy for diffuse large B-cell lymphoma with superior vena cava syndrome in late pregnancy: A case report.SAGE open medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are autoimmune kidney diseases and the most common causes of nephrotic syndrome. Anti-CD20 monoclonal antibodies are now recommended as first-line therapy for MN. Anti-CD20 monoclonal antibodies are also effective in steroid-dependent or frequently relapsing nephrotic syndrome associated with MCD or FSGS. Many women eligible for these treatments are of childbearing age. The impact of anti-CD20 therapies on pregnancy and fetal outcomes remains uncertain, particularly in glomerular diseases. We describe three cases of patients with glomerular disease treated with anti-CD20 therapies in the context of pregnancy and review the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.